Page last updated: 2024-11-13

zhengguangmycin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

zhengguangmycin: antitumor antibiotic complex consisting of more than 10 components; produced by Streptomyces pingyangensis; [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID56841895
MeSH IDM0077080

Synonyms (6)

Synonym
77108-50-0
zhangguangmycin
zhengguangmycin
zhengguangmycin b2
zhengguangmycins
DTXSID80227899

Research Excerpts

Compound-Compound Interactions

ExcerptReferenceRelevance
"To evaluate the effect of locoregional immunotherapy of interleukin 2 (IL-2) in combination with chemotherapy upon intratumoral lymphocytes in oral squamous cell carcinomas."( [Effect of local immunotherapy of interleukin 2(IL-2) in combination with chemotherapy upon intratumoral lymphocytes in oral squamous cell carcinomas].
Hu, Q; Tang, E; Zhou, B, 2003
)
0.32
"To compare the clinical efficacy and toxicity of teniposide (VM26) of higher dose with those of lower dose, both combined with cisplatin (CDDP) and pingyangmycin (PYM), in the treatment of patients with squamous cell carcinoma of oral and maxillofacial region (SCCOMR)."( [Chemotherapy with higher or lower dose of teniposide combined with cisplatin and pingyangmycin for oral squamous cell carcinoma].
Chen, WT; Guo, W; Pan, HY; Qiu, WL; Xu, Q; Ye, DX, 2004
)
0.32
" Thirty-three patients were treated with higher dose of VM26 (total dose was 320 mg) combined with CDDP and PYM (PTP1), the other thirty-two patients were treated with lower dose (total dose was 158 mg) of VM26 combined with CDDP and PYM (PTP2)."( [Chemotherapy with higher or lower dose of teniposide combined with cisplatin and pingyangmycin for oral squamous cell carcinoma].
Chen, WT; Guo, W; Pan, HY; Qiu, WL; Xu, Q; Ye, DX, 2004
)
0.32
"25% and relatively slighter adverse events could be obtained for lower dose of VM26 combined with CDDP and PYM (PTP2)."( [Chemotherapy with higher or lower dose of teniposide combined with cisplatin and pingyangmycin for oral squamous cell carcinoma].
Chen, WT; Guo, W; Pan, HY; Qiu, WL; Xu, Q; Ye, DX, 2004
)
0.32
"To observe the cytotoxicity of chymopapain combined with pingyangmycin (PYM) on mouse hepatoma cell line hapa-6 in vitro."( [Cytotoxicity of chymopapain combined with pingyangmycin on mouse hepatoma cell line hepa-6].
Jiang, X; Jie, W; Taicheng, Y; Xiaoling, C; Yong, G, 2004
)
0.32
" Cooperation effect was showed when three different concentration chymopapain combined with PYM during 48 hours."( [Cytotoxicity of chymopapain combined with pingyangmycin on mouse hepatoma cell line hepa-6].
Jiang, X; Jie, W; Taicheng, Y; Xiaoling, C; Yong, G, 2004
)
0.32
" Cooperation effect was showed when chymopapin was combined with PYM."( [Cytotoxicity of chymopapain combined with pingyangmycin on mouse hepatoma cell line hepa-6].
Jiang, X; Jie, W; Taicheng, Y; Xiaoling, C; Yong, G, 2004
)
0.32

Dosage Studied

ExcerptRelevanceReference
" As determined by a colony-forming assay, the dose-response curves obtained from cells exposed to PYM for 1 h were of one type only: biphasic exponential."( [Anticancer spectrum of pingyangmycin in vitro].
Li, XT, 1990
)
0.28
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (80)

TimeframeStudies, This Drug (%)All Drugs %
pre-199020 (25.00)18.7374
1990's25 (31.25)18.2507
2000's35 (43.75)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.01

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.01 (24.57)
Research Supply Index4.44 (2.92)
Research Growth Index4.45 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.01)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials4 (5.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies1 (1.25%)4.05%
Observational0 (0.00%)0.25%
Other75 (93.75%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]